2017 News Releases

Webcast ImageWebcast
Neuralstem, Inc at BIO CEO & Investor Conference (Replay)
02/13/17 at 8:30 a.m. ET
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
02/16/17Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD).  NSI-189 is a new chemical entity and the lead compound in Neuralstem's neuroge... 
Download PDFPrinter Friendly Version
02/13/17Neuralstem to Present at BIO CEO & Investor Conference
GERMANTOWN, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announces that Rich Daly, Chairman and CEO of Neuralstem, will present at the BIO CEO & Investor Conference at the Waldorf Astoria New York on Monday, February 13, 2017.  The presentation is scheduled at 8:30 am EST. To view the live audio webcast of the presentation please visit... 
Download PDFPrinter Friendly Version
01/06/17Neuralstem Announces a 1-for-13 Reverse Stock Split
GERMANTOWN, Md., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-13. The reverse stock split will become effective on Friday, January 6, 2017 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital M... 
Download PDFPrinter Friendly Version